Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes |
| |
| Authors: | Hinke Simon A |
| |
| Affiliation: | University of Washington, Department of Pharmacology, Seattle, WA 98195, USA. shinke@u.washington.edu |
| |
| Abstract: | Diamyd Medical AB is developing Diamyd (GAD-65), an alum formulation of a full-length recombinant human glutamic acid decarboxylase 65 for subcutaneous injection, for the potential prevention and treatment of type 1 diabetes (T1DM) or latent autoimmune diabetes (LADA) in adults. Phase II clinical trials indicated that Diamyd was safe and well tolerated in patients with T1DM or LADA. Diamyd is currently in phase II/III and III clinical trials for T1DM. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
